<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937350</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009578</org_study_id>
    <secondary_id>R01DK099199</secondary_id>
    <nct_id>NCT02937350</nct_id>
  </id_info>
  <brief_title>Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to better understand vitamin D catabolism and how it is affected by&#xD;
      CKD and race.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specifically, the study team will evaluate the metabolic clearance of 25-hydroxyvitamin D3 in&#xD;
      individuals with varying degrees of CKD and among participants who self-report race as&#xD;
      Caucasian, African American or African. The long-term goal of this work is to enhance the&#xD;
      clinical evaluation and treatment of impaired vitamin D metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic Clearance of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Terminal half-life is equal to ln2/k, where k is the slope of the terminal regression line estimated using ≥3 plasma concentrations. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of D6-25(OH)D3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Volume of distribution in the central compartment is calculated as dose/C0, where dose is the administered dose of 25(OH)D3 and C0 is the initial (estimated) concentration of drug in plasma. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic Formation Clearance of D6-25(OH)D3 Metabolites.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Metabolic formation clearance is calculated as the daughter metabolite plasma AUC divided by the AUC of D6-25(OH)D3 (metabolite/parent AUC ratio). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Serum Concentration of Calcium</measure>
    <time_frame>7 days</time_frame>
    <description>Change in the serum concentration of calcium from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Serum Concentration of Creatinine</measure>
    <time_frame>Baseline, 7 days</time_frame>
    <description>Change in the serum concentration of creatinine from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Serum Concentration of AST</measure>
    <time_frame>Baseline, 7 days</time_frame>
    <description>Change in the serum concentration of AST from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Serum Concentration of ALT</measure>
    <time_frame>Baseline, 7 days</time_frame>
    <description>Change in the serum concentration of ALT from baseline to 7 days after 25(OH)D3 administration</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Study Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D6-25-hydroxyvitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D6-25-hydroxyvitamin D3</intervention_name>
    <description>Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3</description>
    <arm_group_label>Study Population</arm_group_label>
    <other_name>stable isotope deuterium-labeled 25(OH)D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Self-reported race Caucasian, African American, or African&#xD;
&#xD;
          -  Serum total 25(OH)D 10-50 ng/mL&#xD;
&#xD;
          -  Estimated GFR:&#xD;
&#xD;
               -  60 mL/min/1.73m2 (N=40) 15-45 mL/min/1.73m2 (N=40) &lt;15 mL/min/1.73m2, treated&#xD;
                  with hemodialysis (N=40)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Gastric bypass&#xD;
&#xD;
          -  Tuberculosis or sarcoidosis&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic&#xD;
             encephalopathy, bilirubin &gt;=2 mg/dL, serum albumin &lt;=3.5 g/dL, or PT &gt;= 4 seconds)&#xD;
&#xD;
          -  Use of vitamin D3, or vitamin D2 supplements exceeding a mean daily dose of 400 IU,&#xD;
             within 3 months (wash-out allowed)&#xD;
&#xD;
          -  Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce&#xD;
             CYP24A1 within 4 weeks (wash-out allowed)&#xD;
&#xD;
          -  Serum calcium &gt; 10.1 mg/dL&#xD;
&#xD;
          -  Hemoglobin &lt; 10 g/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian de Boer, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>May 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2021</results_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Ian deBoer</investigator_full_name>
    <investigator_title>Professor, Medicine/Nephrology</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>vitamin d catabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02937350/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Controls</title>
          <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
        </group>
        <group group_id="P2">
          <title>CKD Group</title>
          <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
        </group>
        <group group_id="P3">
          <title>Kidney Failure Group</title>
          <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Controls</title>
          <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
        </group>
        <group group_id="B2">
          <title>CKD Group</title>
          <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
        </group>
        <group group_id="B3">
          <title>Kidney Failure Group</title>
          <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10"/>
                    <measurement group_id="B2" value="67" spread="11"/>
                    <measurement group_id="B3" value="58" spread="9"/>
                    <measurement group_id="B4" value="64" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin-D3 Supplement Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Metabolic Clearance of D6-25(OH)D3</title>
        <description>Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Clearance of D6-25(OH)D3</title>
          <description>Metabolic clearance is calculated as the administered dose of 25(OH)D3 divided by the area under the plasma concentration-time curve (AUC). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
          <units>milliliter per day (ml/d)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" spread="108"/>
                    <measurement group_id="O2" value="313" spread="86"/>
                    <measurement group_id="O3" value="263" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of D6-25(OH)D3</title>
        <description>AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of D6-25(OH)D3</title>
          <description>AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
          <units>nanograms x day/mL (ngxd/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="10.2"/>
                    <measurement group_id="O2" value="68.7" spread="10.2"/>
                    <measurement group_id="O3" value="76.6" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life of D6-25(OH)D3</title>
        <description>Terminal half-life is equal to ln2/k, where k is the slope of the terminal regression line estimated using ≥3 plasma concentrations. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life of D6-25(OH)D3</title>
          <description>Terminal half-life is equal to ln2/k, where k is the slope of the terminal regression line estimated using ≥3 plasma concentrations. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
          <units>days (d)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="5.7"/>
                    <measurement group_id="O2" value="25.5" spread="6.5"/>
                    <measurement group_id="O3" value="35.6" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution of D6-25(OH)D3</title>
        <description>Volume of distribution in the central compartment is calculated as dose/C0, where dose is the administered dose of 25(OH)D3 and C0 is the initial (estimated) concentration of drug in plasma. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution of D6-25(OH)D3</title>
          <description>Volume of distribution in the central compartment is calculated as dose/C0, where dose is the administered dose of 25(OH)D3 and C0 is the initial (estimated) concentration of drug in plasma. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
          <units>Liters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="2.9"/>
                    <measurement group_id="O2" value="11.1" spread="2.8"/>
                    <measurement group_id="O3" value="12.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metabolic Formation Clearance of D6-25(OH)D3 Metabolites.</title>
        <description>Metabolic formation clearance is calculated as the daughter metabolite plasma AUC divided by the AUC of D6-25(OH)D3 (metabolite/parent AUC ratio). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Metabolic Formation Clearance of D6-25(OH)D3 Metabolites.</title>
          <description>Metabolic formation clearance is calculated as the daughter metabolite plasma AUC divided by the AUC of D6-25(OH)D3 (metabolite/parent AUC ratio). AUC is calculated using the linear trapezoidal method. Concentration was measured at 5 minutes, 4 hours, and at 1, 4, 7, 14, 21, 28, 42, and 56 days post administration.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.04"/>
                    <measurement group_id="O2" value="0.08" spread="0.03"/>
                    <measurement group_id="O3" value="0.03" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Serum Concentration of Calcium</title>
        <description>Change in the serum concentration of calcium from baseline to 7 days after 25(OH)D3 administration</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Serum Concentration of Calcium</title>
          <description>Change in the serum concentration of calcium from baseline to 7 days after 25(OH)D3 administration</description>
          <units>milligrams/deciliter (mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="1.75"/>
                    <measurement group_id="O2" value="0.16" spread="0.26"/>
                    <measurement group_id="O3" value="-0.27" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Serum Concentration of Creatinine</title>
        <description>Change in the serum concentration of creatinine from baseline to 7 days after 25(OH)D3 administration</description>
        <time_frame>Baseline, 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Serum Concentration of Creatinine</title>
          <description>Change in the serum concentration of creatinine from baseline to 7 days after 25(OH)D3 administration</description>
          <units>milligrams/deciliter (mg/dl)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.09"/>
                    <measurement group_id="O2" value="-0.05" spread="0.27"/>
                    <measurement group_id="O3" value="2.81" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Serum Concentration of AST</title>
        <description>Change in the serum concentration of AST from baseline to 7 days after 25(OH)D3 administration</description>
        <time_frame>Baseline, 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Serum Concentration of AST</title>
          <description>Change in the serum concentration of AST from baseline to 7 days after 25(OH)D3 administration</description>
          <units>units/Liter (u/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="3.43"/>
                    <measurement group_id="O2" value="0.57" spread="5.98"/>
                    <measurement group_id="O3" value="0.10" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Serum Concentration of ALT</title>
        <description>Change in the serum concentration of ALT from baseline to 7 days after 25(OH)D3 administration</description>
        <time_frame>Baseline, 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Controls</title>
            <description>Healthy controls defined as normal eGFR (&gt;60 ml/min per 1.73m2)</description>
          </group>
          <group group_id="O2">
            <title>CKD Group</title>
            <description>CKD group defined as those with eGFR &lt;60ml/min per 1.73 m2)</description>
          </group>
          <group group_id="O3">
            <title>Kidney Failure Group</title>
            <description>Kidney failure group defined as those with ESKD treated with dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Serum Concentration of ALT</title>
          <description>Change in the serum concentration of ALT from baseline to 7 days after 25(OH)D3 administration</description>
          <units>units/Liter (u/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="3.71"/>
                    <measurement group_id="O2" value="1.52" spread="6.92"/>
                    <measurement group_id="O3" value="0.45" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Everyone had the same treatment, so it was more appropriate to summarize AEs for the whole group. Adverse events were not collected separately per arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants (N=87)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain or sensation in arm during infusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ian de Boer</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-616-5403</phone>
      <email>IDeBoer@Nephrology.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

